Charles Schwab Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Charles Schwab Corporation Common Stock trades at $100.2 (market cap $178.33B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: Charles Schwab Corporation Common Stock pays a 1.25% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Charles Schwab Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| SCHW | XBI | |
|---|---|---|
Market Cap | $178.33B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $107.21 | $164.28 |
52-Week Low | $85.35 | $85.16 |
Dividend Yield | 1.25% | — |
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $99.96, down 1.58% on the day, amid strong fundamentals including a 37.99% net income margin and 21.79% ROE. The stock exhibits a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.53 estimated, driven by record revenue and client asset growth. Analyst consensus is bullish with a $120 price target, reflecting 20% upside potential.
Outlook remains positive given consistent earnings beats and robust cash flow, though risks include interest rate sensitivity and competitive pressures. The stock's current valuation at a P/E of 20.39 appears reasonable relative to growth, supporting a favorable risk-reward profile for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →